EFFECTS OF THE 7-NICOTINIC CHOLINERGIC RECEPTOR AGONIST DMXB-A IN SCHIZOPHRENIA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。尽管目前的抗精神病药物有助于治疗精神分裂症的错误信念和错误认知，但许多患者仍然无法工作或社交。精神分裂症患者在注意力和注意力集中方面仍然存在困难，而这对充分发挥功能至关重要。DMXB-A是一种专门针对阿尔法7尼古丁受体的药物，这种受体在精神分裂症中缺乏，被认为是清醒思维所必需的。这种药物在精神分裂症患者的常规药物治疗中得到了越来越多的关注，当一次性给药时是成功的。DMXB-A一次性给药也无副作用。这项研究建议给予DMXB-A 75 mg和150 mg，每天两次，连续4周，以观察注意力的增加是否持续以及药物是否耐受性良好。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although current antipsychotic medications are helpful in treating false beliefs and false perceptions in schizophrenia, many patients are still unable to work or interact socially. People with schizophrenia still have difficulty with paying attention and concentration which re critical to full functioning. DMXB-A is a medication that specifically targets alpha 7 nicotinic receptors, which are deficient in schizophrenia and thought to be necessary for clear thinking. This medication has been successful when given in a one time dose to people with schizophrenia on their regular medications in increasing attention. DMXB-A was also without side effects with the one-time dose. This study proposes to give DMXB-A 75 mg and 150 mg in a twice a day dosing regimen for 4 weeks to see if the gains in attention are continued and if the medication is well tolerated.